GHR106, the First in Class Antibody-based GnRH Antagonist for Broad Clinical Applications
Bibliographic record
Abstract
During the last two decades, our laboratory has identified and studied a GHR106 monoclonal antibody which was generated against N1-29 oligopeptide located in the extracellular domains of human GnRH receptor. GHR106 was shown to exhibit bioactivities as GnRH antagonist, similar to those of small molecules such as Cetrorelix and Elagolix, except that former has a much longer half-life (days vs. hours). Previous studies have indicated that GnRH receptor is localized mainly in anterior pituitary and placenta during pregnancy as well as other reproduction-related tissues in minor amount. It was also known that GnRH receptor is highly expressed among different cancer cells. By using GHR106 and other GnRH antagonists as the target probe, the biological functions of GnRH receptor were found to be tissue-dependent. When acting on the pituitary receptor, GHR106 can cause reversible suppressions of reproductive hormones, such as gonadotropins, E2 and progesterone, whereas HCG and E2, progesterone were suppressed upon targeting to placental GnRH receptor to cause pregnancy terminations. Therefore, we believe that GHR106 is a suitable long acting GnRH antagonist for control of fertility regulations and terminations of ectopic pregnancy and can be used to treat numerous related gynecological diseases. On the other hand, when targeting the same receptor on cancer cells, GHR106 will induce cellular apoptosis to almost all cancer cells. Therefore, GHR106 is also beneficial to immunotherapeutic applications of many human cancers, irrespective of their hormone dependence. Additional modifications of this unique antibody are likely in the future, including CAR (chimeric antigen receptor)-T cell constructs, bispecific antibody formulations and/or antibody drug conjugates. Based on our comprehensive studies, GHR106 can be developed into antibody drugs of multi-indications and could be more beneficial to the existing small molecular GnRH antagonists.
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame machine prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.
Distilled classifier scores by category (both heads)
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.000 | 0.000 |
| Meta-epidemiology (narrow) | 0.001 | 0.000 |
| Meta-epidemiology (broad) | 0.000 | 0.000 |
| Bibliometrics | 0.000 | 0.000 |
| Science and technology studies | 0.000 | 0.000 |
| Scholarly communication | 0.000 | 0.000 |
| Open science | 0.000 | 0.000 |
| Research integrity | 0.001 | 0.001 |
| Insufficient payload (model declined to judge) | 0.003 | 0.002 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".